# Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma – a retrospective study

## TL;DR

Brentuximab vedotin shows quick and tolerable results in treating cutaneous peripheral T cell lymphoma, but the effects don't last long.

## Contribution

This study is the first to systematically evaluate brentuximab vedotin for cutaneous CD30-positive peripheral T cell lymphoma in a small patient cohort.

## Key findings

- Brentuximab vedotin showed good efficacy with a median time to response of 31.5 days.
- Median duration of response was short at 4.3 months, and median overall survival was 15.2 months.
- The treatment was well tolerated, with one patient achieving an almost complete response.

## Abstract

Cutaneous peripheral T cell lymphomas (PTCL) are rare and show an aggressive course with limited response to therapy. The efficacy of brentuximab vedotin in cutaneous peripheral T cell lymphomas has not yet been systematically investigated.

In this retrospective analysis, we evaluated brentuximab vedotin as monotherapy or in combination therapy in patients with cutaneous CD30‐positive peripheral T cell lymphoma (n  =  9).

Overall, the therapy showed good efficacy and acceptable tolerability. One patient achieved an almost complete response, five had a partial response, and two had a mixed response as best overall response. The median time to response was 31.5 days (interquartile range 12–53). The median duration of response was short at 4.3 months. Median overall survival from initiation of brentuximab vedotin was 15.2 months; four of nine patients died from advanced lymphoma and one patient died from an unrelated cause.

Brentuximab vedotin as monotherapy or combination therapy is a rapidly effective and tolerable treatment option for patients with cutaneous PTCL, although the duration of response is short.